- Home
- LQDA vs HCI Comparison
LQDA vs HCI Comparison
Compare LQDA & HCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- HCI
- Stock Information
- Founded
- LQDA 2004
- HCI 2006
- Country
- LQDA United States
- HCI United States
- Employees
- LQDA N/A
- HCI N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- HCI Property-Casualty Insurers
- Sector
- LQDA Health Care
- HCI Finance
- Exchange
- LQDA Nasdaq
- HCI Nasdaq
- Market Cap
- LQDA 1.7B
- HCI 1.7B
- IPO Year
- LQDA 2018
- HCI N/A
- Fundamental
- Price
- LQDA $25.95
- HCI $156.39
- Analyst Decision
- LQDA Strong Buy
- HCI Strong Buy
- Analyst Count
- LQDA 10
- HCI 4
- Target Price
- LQDA $31.40
- HCI $181.25
- AVG Volume (30 Days)
- LQDA 3.4M
- HCI 138.9K
- Earning Date
- LQDA 08-12-2025
- HCI 08-07-2025
- Dividend Yield
- LQDA N/A
- HCI 1.02%
- EPS Growth
- LQDA N/A
- HCI N/A
- EPS
- LQDA N/A
- HCI 11.47
- Revenue
- LQDA $19,322,000.00
- HCI $775,545,000.00
- Revenue This Year
- LQDA $190.73
- HCI $19.25
- Revenue Next Year
- LQDA $421.01
- HCI $4.08
- P/E Ratio
- LQDA N/A
- HCI $13.61
- Revenue Growth
- LQDA 30.20
- HCI 9.67
- 52 Week Low
- LQDA $8.26
- HCI $90.01
- 52 Week High
- LQDA $26.65
- HCI $176.40
- Technical
- Relative Strength Index (RSI)
- LQDA 79.56
- HCI 69.62
- Support Level
- LQDA $19.02
- HCI $136.37
- Resistance Level
- LQDA $26.65
- HCI $158.16
- Average True Range (ATR)
- LQDA 1.53
- HCI 4.59
- MACD
- LQDA 0.64
- HCI 2.51
- Stochastic Oscillator
- LQDA 92.88
- HCI 89.06
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.